Interstitial Lung Disease Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Interstitial Lung Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market.

The Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Interstitial Lung Disease Pipeline Report: https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Interstitial Lung Disease treatment therapies with a considerable amount of success over the years.
• Interstitial Lung Disease companies working in the treatment market are J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Interstitial Lung Disease treatment
• Emerging Interstitial Lung Disease therapies in the different phases of clinical trials are- J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Interstitial Lung Disease market in the coming years.
• In October 2022, Boehringer Ingelheim has commenced a study called "A Double Blind, Randomized, Placebo-controlled Trial Assessing the Effectiveness and Safety of BI 1015550 for a Minimum of 52 Weeks in Individuals with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)." This clinical investigation is available for participation by adult individuals diagnosed with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
• In May 2022, Boehringer Ingelheim revealed Phase II findings for BI 1015550, published in The New England Journal of Medicine (NEJM). The encouraging data spanning 12 weeks demonstrated a decrease in the rate of lung function deterioration among patients diagnosed with idiopathic pulmonary fibrosis (IPF). These promising results are also slated for presentation during the American Thoracic Society (ATS) International Conference Breaking News session scheduled for May 16 in San Francisco.
• In March 2022, Blade Therapeutics has unveiled fresh findings from preclinical studies emphasizing the distinctive features of cudetaxestat, an experimental autotaxin inhibitor under clinical investigation for idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. Cudetaxestat, also known as BLD-0409, operates as a non-competitive and reversible inhibitor of autotaxin, showcasing direct anti-fibrotic effects along with unique preclinical and biochemical traits. These characteristics indicate its potential as a treatment option for lung and liver fibrosis. Furthermore, cudetaxestat has obtained orphan drug designations for treating both IPF and systemic sclerosis.
• In February 2022, Boehringer Ingelheim declared that the US Food and Drug Administration (FDA) awarded Breakthrough Therapy Designation to their innovative investigative treatment, BI 1015550, intended for treating idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral medication categorized as a phosphodiesterase 4B (PDE4B) inhibitor, holding promise in addressing both pulmonary fibrosis-characterized by irreversible lung tissue scarring impacting lung function-and the inflammation linked to progressive fibrosing interstitial lung diseases (ILDs).
• In February 2022, Endeavor BioMedicines has disclosed the finalization of a $101 million Series B funding round, spearheaded by Ally Bridge Group and Avidity Partners. The raised capital will bolster the progression of Endeavor's portfolio projects, notably ENV-101 (taladegib), a small molecule inhibitor targeting the PTCH1 receptor within the Hedgehog signaling pathway, aimed at treating cancer and idiopathic pulmonary fibrosis (IPF). Additionally, the funding will aid ENV-201, a potentially leading-edge small molecule inhibitor of ULK1/2 intended for treating KRAS-driven cancers.
• In January 2022, Horizon Therapeutics has announced the enrollment of the first patient in a Phase IIb pivotal trial to assess its developmental medication, HZN-825, functioning as a lysophosphatidic acid receptor 1 (LPAR1) antagonist designed for individuals with idiopathic pulmonary fibrosis (IPF), the most prevalent form of interstitial lung disease. HZN-825 is an orally administered selective LPAR1 antagonist that has demonstrated initial positive effects in clinical impact related to systemic sclerosis. The signaling of LPAR1 is associated with fibrosis and inflammation, and both preclinical and clinical evidence supports the potential of LPAR1 antagonism to combat fibrosis across various organ systems, including the lungs and skin.


Interstitial Lung Disease Overview
Interstitial lung disease (ILD) refers to a diverse group of lung disorders affecting the interstitium, which is the tissue and space surrounding the air sacs (alveoli) in the lungs. The interstitium is made up of the walls of the air sacs and the small blood vessels.

Get a Free Sample PDF Report to know more about Interstitial Lung Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Interstitial Lung Disease Drugs Under Different Phases of Clinical Development Include:
• J2H P1905: J2H Biotech
• CR405: Crystec Pharma
• APT-101: Apie Therapeutics
• BLR-200: BLR Bio
• M-156: ImmunoMet Therapeutics
• AD-214: AdAlta Limited
• Vixarelimab: Genentech
• Abatacept: Bristol-Myers Squibb
• HEC585: Sunshine Lake Pharma
• Efzofitimod: aTyr Pharma
• Pamrevlumab: FibroGen
• BI-1015550: Boehringer Ingelheim

Interstitial Lung Disease Route of Administration
Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Interstitial Lung Disease Molecule Type
Interstitial Lung Disease Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Interstitial Lung Disease Pipeline Therapeutics Assessment
• Interstitial Lung Disease Assessment by Product Type
• Interstitial Lung Disease By Stage and Product Type
• Interstitial Lung Disease Assessment by Route of Administration
• Interstitial Lung Disease By Stage and Route of Administration
• Interstitial Lung Disease Assessment by Molecule Type
• Interstitial Lung Disease by Stage and Molecule Type

DelveInsight's Interstitial Lung Disease Report covers around 120+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Interstitial Lung Disease product details are provided in the report. Download the Interstitial Lung Disease pipeline report to learn more about the emerging Interstitial Lung Disease therapies at:
https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Interstitial Lung Disease Therapeutics Market include:
Key companies developing therapies for Interstitial Lung Disease are - Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, and others.

Interstitial Lung Disease Pipeline Analysis:
The Interstitial Lung Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Disease Treatment.
• Interstitial Lung Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Interstitial Lung Disease drugs and therapies-
https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Interstitial Lung Disease Pipeline Market Drivers
• Increase in prevalence of Interstitial Lung Disease (ILD), increase in geriatric population are some of the important factors that are fueling the Interstitial Lung Disease Market.

Interstitial Lung Disease Pipeline Market Barriers
• However, frequent misdiagnosis of the disease, costly and invasive diagnostic procedures and other factors are creating obstacles in the Interstitial Lung Disease Market growth.

Scope of Interstitial Lung Disease Pipeline Drug Insight
• Coverage: Global
• Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others
• Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others
• Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies
• Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers

Request for Sample PDF Report for Interstitial Lung Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Interstitial Lung Disease Report Introduction
2. Interstitial Lung Disease Executive Summary
3. Interstitial Lung Disease Overview
4. Interstitial Lung Disease- Analytical Perspective In-depth Commercial Assessment
5. Interstitial Lung Disease Pipeline Therapeutics
6. Interstitial Lung Disease Late Stage Products (Phase II/III)
7. Interstitial Lung Disease Mid Stage Products (Phase II)
8. Interstitial Lung Disease Early Stage Products (Phase I)
9. Interstitial Lung Disease Preclinical Stage Products
10. Interstitial Lung Disease Therapeutics Assessment
11. Interstitial Lung Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Interstitial Lung Disease Key Companies
14. Interstitial Lung Disease Key Products
15. Interstitial Lung Disease Unmet Needs
16 . Interstitial Lung Disease Market Drivers and Barriers
17. Interstitial Lung Disease Future Perspectives and Conclusion
18. Interstitial Lung Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Interstitial Lung Disease Market https://www.delveinsight.com/report-store/interstitial-lung-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Interstitial Lung Disease Epidemiology https://www.delveinsight.com/report-store/interstitial-lung-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Interstitial Lung Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Lung Transplant Rejection Market https://www.delveinsight.com/report-store/lung-transplant-rejection-market
DelveInsight's "Lung Transplant Rejection Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Lung Transplant Rejection, historical and forecasted epidemiology as well as the Lung Transplant Rejection market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

CAR T-Cell Therapy for Multiple Myeloma Market
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
DelveInsight's "CAR-T Cell Therapy for Multiple Myeloma Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma and various CAR-Ts used in multiple myeloma, and CAR-Ts historical and forecasted market trends in multiple myeloma in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Insulin Resistance Market
https://www.delveinsight.com/report-store/insulin-resistance-market
DelveInsight's "Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dyskinesia Market
https://www.delveinsight.com/report-store/dyskinesia-market
DelveInsight's "Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dyskinesia, historical and forecasted epidemiology as well as the Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemophilia Market
https://www.delveinsight.com/report-store/hemophilia-market
DelveInsight's "Hemophilia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Paroxysmal Nocturnal Hemoglobinuria Market
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, the EU4 (Germany, France, Italy, Spain), the UK and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.